Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261


Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.


TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

Cazzola A, Schlegel C, Jansen I, Bochtler T, Jauch A, Krämer A.

Leukemia. 2019 Aug 23. doi: 10.1038/s41375-019-0550-5. [Epub ahead of print]


Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.


Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.


Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8. No abstract available.


Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma.

Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, Hillengass J, Goldschmidt H, Dimitrakopoulou-Strauss A.

Haematologica. 2019 Sep;104(9):e420-e423. doi: 10.3324/haematol.2018.213041. Epub 2019 Feb 14. No abstract available.


Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.


Autophagic cell death restricts chromosomal instability during replicative crisis.

Nassour J, Radford R, Correia A, Fusté JM, Schoell B, Jauch A, Shaw RJ, Karlseder J.

Nature. 2019 Jan;565(7741):659-663. doi: 10.1038/s41586-019-0885-0. Epub 2019 Jan 23.


Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells.

Thier MC, Hommerding O, Panten J, Pinna R, García-González D, Berger T, Wörsdörfer P, Assenov Y, Scognamiglio R, Przybylla A, Kaschutnig P, Becker L, Milsom MD, Jauch A, Utikal J, Herrmann C, Monyer H, Edenhofer F, Trumpp A.

Cell Stem Cell. 2019 Jan 3;24(1):166-182.e13. doi: 10.1016/j.stem.2018.11.015. Epub 2018 Dec 20.


Effects of a Pasty Bone Cement Containing Brain-Derived Neurotrophic Factor-Functionalized Mesoporous Bioactive Glass Particles on Metaphyseal Healing in a New Murine Osteoporotic Fracture Model.

Kauschke V, Schneider M, Jauch A, Schumacher M, Kampschulte M, Rohnke M, Henss A, Bamberg C, Trinkaus K, Gelinsky M, Heiss C, Lips KS.

Int J Mol Sci. 2018 Nov 9;19(11). pii: E3531. doi: 10.3390/ijms19113531.


Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors.

Ratnaparkhe M, Wong JKL, Wei PC, Hlevnjak M, Kolb T, Simovic M, Haag D, Paul Y, Devens F, Northcott P, Jones DTW, Kool M, Jauch A, Pastorczak A, Mlynarski W, Korshunov A, Kumar R, Downing SM, Pfister SM, Zapatka M, McKinnon PJ, Alt FW, Lichter P, Ernst A.

Nat Commun. 2018 Nov 12;9(1):4760. doi: 10.1038/s41467-018-06925-4.


Micronucleus formation in human cancer cells is biased by chromosome size.

Bochtler T, Kartal-Kaess M, Granzow M, Hielscher T, Cosenza MR, Herold-Mende C, Jauch A, Krämer A.

Genes Chromosomes Cancer. 2019 Jun;58(6):392-395. doi: 10.1002/gcc.22707. Epub 2019 Jan 17.


Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.


Topokaryotyping demonstrates single cell variability and stress dependent variations in nuclear envelope associated domains.

Jurisic A, Robin C, Tarlykov P, Siggens L, Schoell B, Jauch A, Ekwall K, Sørensen CS, Lipinski M, Shoaib M, Ogryzko V.

Nucleic Acids Res. 2018 Dec 14;46(22):e135. doi: 10.1093/nar/gky818.


CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.


Systems Thinking Education in RN-BSN Programs: A Regional Study.

Stalter AM, Jauch A.

Nurse Educ. 2019 Mar/Apr;44(2):112-115. doi: 10.1097/NNE.0000000000000558.


Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.


Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.


Nano-scale microfluidics to study 3D chemotaxis at the single cell level.

Frick C, Dettinger P, Renkawitz J, Jauch A, Berger CT, Recher M, Schroeder T, Mehling M.

PLoS One. 2018 Jun 7;13(6):e0198330. doi: 10.1371/journal.pone.0198330. eCollection 2018.


Mitochondria-Endoplasmic Reticulum Contact Sites Function as Immunometabolic Hubs that Orchestrate the Rapid Recall Response of Memory CD8+ T Cells.

Bantug GR, Fischer M, Grählert J, Balmer ML, Unterstab G, Develioglu L, Steiner R, Zhang L, Costa ASH, Gubser PM, Burgener AV, Sauder U, Löliger J, Belle R, Dimeloe S, Lötscher J, Jauch A, Recher M, Hönger G, Hall MN, Romero P, Frezza C, Hess C.

Immunity. 2018 Mar 20;48(3):542-555.e6. doi: 10.1016/j.immuni.2018.02.012. Epub 2018 Mar 6.


Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Yadav P, Merz M, Mai EK, Försti A, Jauch A, Goldschmidt H, Hemminki K.

Haematologica. 2018 Apr;103(4):e162-e164. doi: 10.3324/haematol.2017.184226. Epub 2018 Feb 1. No abstract available.


Systems thinking and incivility in nursing practice: An integrative review.

Phillips JM, Stalter AM, Winegardner S, Wiggs C, Jauch A.

Nurs Forum. 2018 Jan 23. doi: 10.1111/nuf.12250. [Epub ahead of print]


Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.


Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2018 Jan 9;2(1):1-9. doi: 10.1182/bloodadvances.2017013334.


Murine transgenic embryonic stem cell lines for the investigation of sinoatrial node-related molecular pathways.

Schmitteckert S, Griesbeck A, Sumer S, Jauch A, Rolletschek A, Niesler B, Rappold GA, Hoffmann S.

Stem Cell Res. 2017 Dec;25:278-282. doi: 10.1016/j.scr.2017.07.011. Epub 2017 Jul 11.


Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.


Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency.

Marquardsen FA, Baldin F, Wunderer F, Al-Herz W, Mikhael R, Lefranc G, Baz Z, Rezaee F, Hanna R, Kfir-Erenfeld S, Stepensky P, Meyer B, Jauch A, Bigler MB, Burgener AV, Higgins R, Navarini AA, Church JA, Chou J, Geha R, Notarangelo LD, Hess C, Berger CT, Bloch DB, Recher M.

J Clin Immunol. 2017 Oct;37(7):707-714. doi: 10.1007/s10875-017-0431-5. Epub 2017 Aug 21.


Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.


Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Meziane I, Huhn S, Filho MIDS, Weinhold N, Campo C, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Jauch A, Morgan GJ, Houlston R, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Försti A, Schönland SO, Hemminki K.

Haematologica. 2017 Oct;102(10):e411-e414. doi: 10.3324/haematol.2017.171108. Epub 2017 Jul 4. No abstract available.


Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia.

Wang W, Stiehl T, Raffel S, Hoang VT, Hoffmann I, Poisa-Beiro L, Saeed BR, Blume R, Manta L, Eckstein V, Bochtler T, Wuchter P, Essers M, Jauch A, Trumpp A, Marciniak-Czochra A, Ho AD, Lutz C.

Haematologica. 2017 Sep;102(9):1567-1577. doi: 10.3324/haematol.2016.163584. Epub 2017 May 26.


AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.

Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, Ho AD, Hegenbart U, Schönland SO.

Blood. 2017 Aug 3;130(5):632-642. doi: 10.1182/blood-2017-02-767475. Epub 2017 May 26.


Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.


Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.


Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.


Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, Hemminki K, Goldschmidt H, Schönland SO, Jauch A.

Haematologica. 2017 Jul;102(7):1281-1290. doi: 10.3324/haematol.2016.160721. Epub 2017 Mar 24.


Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis.

Ratnaparkhe M, Hlevnjak M, Kolb T, Jauch A, Maass KK, Devens F, Rode A, Hovestadt V, Korshunov A, Pastorczak A, Mlynarski W, Sungalee S, Korbel J, Hoell J, Fischer U, Milde T, Kramm C, Nathrath M, Chrzanowska K, Tausch E, Takagi M, Taga T, Constantini S, Loeffen J, Meijerink J, Zielen S, Gohring G, Schlegelberger B, Maass E, Siebert R, Kunz J, Kulozik AE, Worst B, Jones DT, Pfister SM, Zapatka M, Lichter P, Ernst A.

Leukemia. 2017 Oct;31(10):2048-2056. doi: 10.1038/leu.2017.55. Epub 2017 Feb 15.


Epstein-Barr virus particles induce centrosome amplification and chromosomal instability.

Shumilov A, Tsai MH, Schlosser YT, Kratz AS, Bernhardt K, Fink S, Mizani T, Lin X, Jauch A, Mautner J, Kopp-Schneider A, Feederle R, Hoffmann I, Delecluse HJ.

Nat Commun. 2017 Feb 10;8:14257. doi: 10.1038/ncomms14257.


Transcriptomes reflect the phenotypes of undifferentiated, granulocyte and macrophage forms of HL-60/S4 cells.

Mark Welch DB, Jauch A, Langowski J, Olins AL, Olins DE.

Nucleus. 2017 Mar 4;8(2):222-237. doi: 10.1080/19491034.2017.1285989.


Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Endris V, Kirchner M, Stenzinger A, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. doi: 10.1182/blood-2016-09-738161. Epub 2017 Jan 24.


Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.

da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.

Leukemia. 2017 Aug;31(8):1735-1742. doi: 10.1038/leu.2016.387. Epub 2016 Dec 27.


Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M.

J Allergy Clin Immunol. 2017 Mar;139(3):1043-1046.e5. doi: 10.1016/j.jaci.2016.08.042. Epub 2016 Nov 28. No abstract available.


Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.

Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.


Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients.

Wang W, Foerner E, Buss E, Jauch A, Eckstein V, Wuchter P, Ho AD, Lutz C.

Leuk Lymphoma. 2017 Jun;58(6):1446-1454. doi: 10.1080/10428194.2016.1236378. Epub 2016 Oct 13.


Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.


Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

Kortüm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS.

Blood. 2016 Sep 1;128(9):1226-33. doi: 10.1182/blood-2016-02-698092. Epub 2016 Jul 25.


Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.


Memory CD8(+) T Cells Require Increased Concentrations of Acetate Induced by Stress for Optimal Function.

Balmer ML, Ma EH, Bantug GR, Grählert J, Pfister S, Glatter T, Jauch A, Dimeloe S, Slack E, Dehio P, Krzyzaniak MA, King CG, Burgener AV, Fischer M, Develioglu L, Belle R, Recher M, Bonilla WV, Macpherson AJ, Hapfelmeier S, Jones RG, Hess C.

Immunity. 2016 Jun 21;44(6):1312-24. doi: 10.1016/j.immuni.2016.03.016. Epub 2016 May 17.


Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.

Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, Škifić M, Michel K, Eising B, Lucchini G, Bakhtiar S, Greil J, Lang P, Basu O, von Luettichau I, Schulz A, Sykora KW, Jarisch A, Soerensen J, Salzmann-Manrique E, Seifried E, Klingebiel T, Bader P, Kuçi S.

Haematologica. 2016 Aug;101(8):985-94. doi: 10.3324/haematol.2015.140368. Epub 2016 May 12.


Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.


Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M.

Cancer Med. 2016 Jul;5(7):1464-72. doi: 10.1002/cam4.725. Epub 2016 Apr 25.

Supplemental Content

Support Center